Schardt Awarded UMD-NCI Cancer Research Training Fellowship

Schardt Awarded UMD-NCI Cancer Research Training Fellowship

Bookmark and Share



Fischell Department of Bioengineering (BioE) third-year graduate student John Schardt was awarded a joint University of Maryland-National Cancer Institute (UMD-NCI) Cancer Research Training Fellowship. The award carries tuition remission, a full stipend, and funding for lab supplies for one year, with potential renewal. 

Schardt, a student in BioE Assistant Professor Steven Jay's Vascular Pharmacoengineering and Biotherapeutics Laboratory, was recognized for his efforts to develop a novel molecular engineering approach to breast and ovarian cancer therapy. 

Schardt's project involves designing a strategy to overcome dysregulation of signaling between protein ligands and their cell surface receptors - specialized integral membrane proteins that communicate signals between the cell and the outside world - which can lead to tumor growth and metastasis in many cancers. One example of this dysregulation, which is especially prevalent in breast and ovarian cancers, is the overexpression of the receptor HER3. This overexpression often leads to amplification of HER3 signaling pathways, which generally cause negative outcomes such as tumor progression and/or metastasis. 

Along with Jay, UMD principal investigator on the project, and Dr. Stanley Lipkowitz, NCI principal investigator, Schardt has helped pioneer a strategy to inhibit HER3 signaling in cancer referred to as “HER3 sequestration.” Their technique involves engineering multivalent HER3 ligands to trap HER3 into configurations that prevent its interaction with other receptors that are necessary to initiate pro-neoplastic signaling.

Through the fellowship, Schardt will employ computational protein design and cancer biology experimental approaches to better understand and enhance HER3 sequestration towards the development of a next generation of multivalent HER3 ligands that could be translated into novel cancer therapeutics.

 

About the UMD-NCI Partnership for Cancer Technology

The UMD-NCI Partnership for Cancer Technology was established to bring together the expertise and resources in the mathematical sciences, physical sciences, and engineering at the University of Maryland with basic, clinical, and translational research expertise of the National Cancer Institute/Center for Cancer Research to solve the most pressing problems in cancer research. The partnership was officially formed in May 2010. More information is available online.

September 18, 2015


Prev   Next

Current Headlines

University of Maryland Ranks Among Top 100 Worldwide for Patents

UMD Awarded $6 Million NIH Grant for Structure-Based Design of a Hepatitis C Vaccine

University of Maryland Joins Grand Coalition to Support Paris Agreement Climate Action

UMD-Led Research in Bloodless Worms Reveals How Organs Communicate Their Status of Life-Giving Heme

HUD Housing Assistance Linked to Improved Health Care Access

Gravitational Waves Detected a Third Time

UMD Names Laurie E. Locascio Vice President for Research

Unexpectedly Primitive Atmosphere Found Around Distant "Warm Neptune"

News Resources

Return to Newsroom

Search News

Archived News

Events Resources

Events Calendar

Additional Resources

UM Newsdesk

Faculty Experts

Connect

social iconsFacebookTwitterLinkedInResearch News RSS Feed
Office of Technology Commercialization
2130 Mitchell Building
7999 Regents Dr.
University of Maryland
College Park, MD 20742

Phone: 301-405-3947  |  Fax: 301-314-9502
Email: umdtechtransfer@umd.edu

© Copyright 2013 University of Maryland

Did You Know

UMD's Neutral Buoyancy Research Facility, which simulates weightlessness, is one of only two such facilities in the U.S.